Impel Pharmaceuticals Inc.

Impel Neuropharma, Inc.

Pharma Seeds Create, LLC

Aditya R Das

John D Hoekman

Kelsey H Satterly

Inna Dashevsky

Stephen B Shrewsbury

Gregory J Davies

Bhavin Y Gajera

Toru Hibi

Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (C) of at least 30 ng/mL, with (b) a mean time to C(T) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

Intranasal delivery of olanzapine by precision olfactory device

A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.

Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's disease

Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease

Growing community of inventors

Foster City, CA, United States of America

Aditya R Das